Global Gynecological Cancers Market Research and Forecast, 2018-2023
Global gynecological cancers market is predicted to grow significantly during the forecast period (2018-2023). There are various types of gynecological cancer such as ovarian cancer, cervical cancer, uterine cancer and so forth. The rising prevalence of gynecological cancers has been the major factor driving market growth during the forecast period. As per American Medical Association (AMA), globally 526,000 of cervical cancers incidences were recorded followed by 251,000 incidences of ovarian cancer in 2015. Such a high prevalence of these cancers raises the demand for diagnosis and treatment. Additionally, a strong pipeline of drugs has been motivating the market as more than 5,920 trials of gynecological cancer drugs market have been witnessed in recent years. Moreover, government support for the development of novel drugs for these cancers is also affecting the market in a positive manner. Furthermore, rising healthcare expenditure, as well as support from government and public & private organizations for women health are enabling market growth.
However, several factors such as high cost of gynecological cancer diagnosis and treatment along with lack of reimbursement policies in middle-income and low-income countries act a major restraint in the growth of the global gynecological cancer market. The overall cost of ovarian cancer treatment range between $20,000 to $200,000 in most of the countries which is a large amount to be paid without health insurance. Additionally, the lack of awareness has been recorded towards women health including cancer diagnosis and treatment in various countries that hinder the market growth. Though these factors affect the present market, emerging opportunities in emerging economies will drive future market growth. Moreover, continuous research and development for drug discovery of gynecological cancer are expected to be significant contributors for the market in near future.
North America dominates the global gynecological market due to high healthcare spending and awareness among population towards the different types of cancers’ diagnosis and treatment. Additionally, the availability of adequate reimbursement policies and drug discovery in the region motivates the market. Moreover, the Asia-Pacific region has been predicted as the fastest growing region due to developing healthcare infrastructure and raising awareness towards gynecological cancer in the region. Moreover, government initiatives for women health in Asian countries enable market growth in the country.
The key players of the global gynecological market include Abbott Laboratories, Inc., Becton, Dickinson and Co., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer, Inc. and so forth. Merger & acquisition, R&D, partnership, product launch, and collaboration are the key winning strategies adopted by market players across the globe.
RESEARCH METHODOLOGY
The market study of the global gynecological market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The OMR team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. The numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analysts to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to get first-hand information. Primary research brings authenticity to our reports.
SECONDARY SOURCES INCLUDE
MARKET SEGMENTATION
However, several factors such as high cost of gynecological cancer diagnosis and treatment along with lack of reimbursement policies in middle-income and low-income countries act a major restraint in the growth of the global gynecological cancer market. The overall cost of ovarian cancer treatment range between $20,000 to $200,000 in most of the countries which is a large amount to be paid without health insurance. Additionally, the lack of awareness has been recorded towards women health including cancer diagnosis and treatment in various countries that hinder the market growth. Though these factors affect the present market, emerging opportunities in emerging economies will drive future market growth. Moreover, continuous research and development for drug discovery of gynecological cancer are expected to be significant contributors for the market in near future.
North America dominates the global gynecological market due to high healthcare spending and awareness among population towards the different types of cancers’ diagnosis and treatment. Additionally, the availability of adequate reimbursement policies and drug discovery in the region motivates the market. Moreover, the Asia-Pacific region has been predicted as the fastest growing region due to developing healthcare infrastructure and raising awareness towards gynecological cancer in the region. Moreover, government initiatives for women health in Asian countries enable market growth in the country.
The key players of the global gynecological market include Abbott Laboratories, Inc., Becton, Dickinson and Co., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer, Inc. and so forth. Merger & acquisition, R&D, partnership, product launch, and collaboration are the key winning strategies adopted by market players across the globe.
RESEARCH METHODOLOGY
The market study of the global gynecological market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The OMR team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. The numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analysts to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to get first-hand information. Primary research brings authenticity to our reports.
SECONDARY SOURCES INCLUDE
- Financial reports of companies involved in the market
- Whitepapers, research-papers and news blogs
- Company websites and their product catalog
MARKET SEGMENTATION
- Global Gynecological Market Research and Analysis by Cancer Type
- Global Gynecological Market Research and Analysis by Diagnosis
- Global Gynecological Market Research and Analysis by Therapeutic Modality
- Global Gynecological Market Research and Analysis by End-User
- Comprehensive research methodology of the global gynecological cancers market.
- This report also includes a detailed and extensive market overview with analyst insights & key market trends.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global gynecological cancers market.
- Insights about market determinants which are stimulating the global gynecological cancers market.
- Detailed and extensive market segments with regional distribution of forecast revenues.
- Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Regulations
3. MARKET DETERMINANTS
3.1. Motivators
3.1.1. Rising Prevalence of Gynecological Cancers
3.1.2. Rising Initiatives for Women Health
3.1.3. Government and Private Organizations Support for Development of Novel Drugs for Gynecological Cancer
3.1.4. Strong Pipeline for Drugs
3.2. Restraints
3.2.1. High Costs of Treatment
3.2.2. Lack of Reimbursement Policies in Under-Developed Countries
3.2.3. Low Awareness Among Developing Countries Population
3.3. Opportunities
3.3.1. Extensive R&D and Drug Discovery
3.3.2. Emerging Markets in Emerging Economies
4. MARKET SEGMENTATION
4.1. Global Gynecological Cancer Market by Type
4.1.1. Cervical Cancer
4.1.2. Ovarian Cancer
4.1.3. Uterine Cancer
4.1.4. Vaginal Cancer
4.1.5. Vulvar Cancer
4.1.6. Others (Fallopian Tube Cancer)
4.2. Global Gynecological Cancer Market by Diagnosis
4.2.1. Colposcopy
4.2.2. Biopsy test
4.2.3. Human papillomavirus (HPV) tests
4.2.4. Imaging test
4.2.4.1. Intravenous Urography
4.2.4.2. Positron Emission Tomography (PET Scan)
4.2.4.3. Computed Tomography (CT)
4.2.4.4. Magnetic Resonance Imaging (MRI)
4.2.4.5. Others
4.2.5. Others (Pelvic Test)
4.3. Global Gynecological Cancer Market by Therapeutic Modality
4.3.1. Chemotherapy
4.3.2. Radiation Therapy
4.3.3. Hormonal Therapy
4.3.4. Immunotherapy
4.4. Global Gynecological Cancer Market by End-Users
4.4.1. Hospitals and Surgical Centres
4.4.2. Diagnostic Centres
4.4.3. Others (Research Institutions)
5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis
6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. COMPANY PROFILES
7.1. Abbott Laboratories, Inc.
7.2. AstraZeneca, PLC
7.3. Becton, Dickinson and Co.
7.4. Boehringer Ingelheim GmbH
7.5. Bristol Myers Squibb Co.
7.6. Caris Life Sciences, Inc.
7.7. Eli Lilly and Co.
7.8. F. Hoffmann-La Roche, Ltd.
7.9. Genentech, Inc.
7.10. GlaxoSmithKline PLC
7.11. Hologic, Inc.
7.12. Janssen Pharmaceuticals, Inc.
7.13. Kazia Therapeutics, Ltd.
7.14. Merck & Co., Inc.
7.15. NuCana PLC
7.16. Pfizer, Inc.
7.17. Sanofi S.A.
7.18. Siemens Healthcare GmbH
7.19. Takeda Pharmaceuticals Co., Ltd.
7.20. Teva Pharmaceuticals, Ltd.
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Regulations
3. MARKET DETERMINANTS
3.1. Motivators
3.1.1. Rising Prevalence of Gynecological Cancers
3.1.2. Rising Initiatives for Women Health
3.1.3. Government and Private Organizations Support for Development of Novel Drugs for Gynecological Cancer
3.1.4. Strong Pipeline for Drugs
3.2. Restraints
3.2.1. High Costs of Treatment
3.2.2. Lack of Reimbursement Policies in Under-Developed Countries
3.2.3. Low Awareness Among Developing Countries Population
3.3. Opportunities
3.3.1. Extensive R&D and Drug Discovery
3.3.2. Emerging Markets in Emerging Economies
4. MARKET SEGMENTATION
4.1. Global Gynecological Cancer Market by Type
4.1.1. Cervical Cancer
4.1.2. Ovarian Cancer
4.1.3. Uterine Cancer
4.1.4. Vaginal Cancer
4.1.5. Vulvar Cancer
4.1.6. Others (Fallopian Tube Cancer)
4.2. Global Gynecological Cancer Market by Diagnosis
4.2.1. Colposcopy
4.2.2. Biopsy test
4.2.3. Human papillomavirus (HPV) tests
4.2.4. Imaging test
4.2.4.1. Intravenous Urography
4.2.4.2. Positron Emission Tomography (PET Scan)
4.2.4.3. Computed Tomography (CT)
4.2.4.4. Magnetic Resonance Imaging (MRI)
4.2.4.5. Others
4.2.5. Others (Pelvic Test)
4.3. Global Gynecological Cancer Market by Therapeutic Modality
4.3.1. Chemotherapy
4.3.2. Radiation Therapy
4.3.3. Hormonal Therapy
4.3.4. Immunotherapy
4.4. Global Gynecological Cancer Market by End-Users
4.4.1. Hospitals and Surgical Centres
4.4.2. Diagnostic Centres
4.4.3. Others (Research Institutions)
5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis
6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. COMPANY PROFILES
7.1. Abbott Laboratories, Inc.
7.2. AstraZeneca, PLC
7.3. Becton, Dickinson and Co.
7.4. Boehringer Ingelheim GmbH
7.5. Bristol Myers Squibb Co.
7.6. Caris Life Sciences, Inc.
7.7. Eli Lilly and Co.
7.8. F. Hoffmann-La Roche, Ltd.
7.9. Genentech, Inc.
7.10. GlaxoSmithKline PLC
7.11. Hologic, Inc.
7.12. Janssen Pharmaceuticals, Inc.
7.13. Kazia Therapeutics, Ltd.
7.14. Merck & Co., Inc.
7.15. NuCana PLC
7.16. Pfizer, Inc.
7.17. Sanofi S.A.
7.18. Siemens Healthcare GmbH
7.19. Takeda Pharmaceuticals Co., Ltd.
7.20. Teva Pharmaceuticals, Ltd.
LIST OF TABLES
TABLE # 1 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLIONS)
TABLE # 2 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL CERVICAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL OVARIAN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL UTERINE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL VAGINAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL VULVAR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL OTHER GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL COLPOSCOPY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL BIOPSY TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL IMAGING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL HUMAN PAPILLOMAVIRUS TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL OTHER TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 15 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPEUTIC MODALITY 2017-2023 ($ MILLION)
TABLE # 16 GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 17 GLOBAL RADIATION THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 18 GLOBAL HORMONAL THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 19 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 20 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 21 GLOBAL HOSPITALS AND SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 22 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 23 GLOBAL OTHERS GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 24 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 25 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 26 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 27 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 28 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 29 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 30 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 31 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 32 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 33 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 34 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 35 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 36 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 37 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 38 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 39 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 40 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 41 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 42 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 1 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLIONS)
TABLE # 2 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL CERVICAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL OVARIAN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL UTERINE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL VAGINAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL VULVAR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL OTHER GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL COLPOSCOPY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL BIOPSY TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL IMAGING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL HUMAN PAPILLOMAVIRUS TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL OTHER TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 15 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPEUTIC MODALITY 2017-2023 ($ MILLION)
TABLE # 16 GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 17 GLOBAL RADIATION THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 18 GLOBAL HORMONAL THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 19 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 20 GLOBAL GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 21 GLOBAL HOSPITALS AND SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 22 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 23 GLOBAL OTHERS GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 24 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 25 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 26 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 27 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 28 NORTH AMERICAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 29 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 30 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 31 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 32 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 33 EUROPEAN GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 34 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 35 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 36 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 37 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
TABLE # 38 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 39 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 40 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
TABLE # 41 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC MODALITY, 2017-2023 ($ MILLION)
TABLE # 42 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE # 1 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY CANCER TYPE, 2017-2023 (%)
FIGURE # 2 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY DIAGNOSIS, 2017-2023 (%)
FIGURE # 3 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY THERAPEUTIC MODALITY, 2017-2023 (%)
FIGURE # 4 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY END-USERS, 2017-2023 (%)
FIGURE # 5 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY GEOGRAPHY, 2017-2023 (%)
FIGURE # 6 NORTH AMERICA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 UNITED STATES GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 CANADA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 EUROPE GYNECOLOGICAL CANCER S MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 UK GYNECOLOGICAL CANCER S MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 FRANCE GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 SPAIN GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 GERMANY GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 ITALY GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 ROE GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 17 INDIA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 18 CHINA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 19 JAPAN GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 20 REST OF ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 21 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 1 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY CANCER TYPE, 2017-2023 (%)
FIGURE # 2 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY DIAGNOSIS, 2017-2023 (%)
FIGURE # 3 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY THERAPEUTIC MODALITY, 2017-2023 (%)
FIGURE # 4 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY END-USERS, 2017-2023 (%)
FIGURE # 5 GLOBAL GYNECOLOGICAL CANCER MARKET SHARE BY GEOGRAPHY, 2017-2023 (%)
FIGURE # 6 NORTH AMERICA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 UNITED STATES GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 CANADA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 EUROPE GYNECOLOGICAL CANCER S MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 UK GYNECOLOGICAL CANCER S MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 FRANCE GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 SPAIN GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 GERMANY GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 ITALY GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 ROE GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 17 INDIA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 18 CHINA GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 19 JAPAN GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 20 REST OF ASIA-PACIFIC GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 21 REST OF THE WORLD GYNECOLOGICAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
